The U.S. section of Abbottep.com is a product-specific website that is NOT intended for non U.S. residents. This web content is exclusively reserved for health care professionals in the United States.

Do you wish to continue to visit the Abbottep.com U.S. section?

Get your rhythm back.

Serious heart rhythm disorders called arrhythmias, affect the lives of millions of people daily. Unfortunately, most treatments for these conditions are generic and one-size-fits-all, with mixed results.

But there’s hope.

We believe there is a better way to address serious heart rhythm disorders such as atrial fibrillation and ventricular tachycardia. Using Abbott Electrophysiology’s technology, doctors can identify the sources of arrhythmias that are unique to each person. Now treatment can be tailored to your individual needs.

Find Your Source.
Get Tailored Therapy.
Get Your Rhythm Back.

Find a doctor near you who is using the Topera Rotor Mapping System

The most common heart rhythm disorder, atrial fibrillation (AF, or afib) is a serious global public health problem which affects millions of people around the world. If left untreated, AF doubles the risk of heart-related deaths and also increases stroke risk by up to 500%. Unfortunately, although it is such a serious health problem, AF has historically been difficult to treat with an acceptable degree of success.

In response to this unaddressed need, Abbott, Inc. has developed a unique 3D analysis and mapping solutions (the Abbott 3D Mapping System), which consists of the RhythmView Workstation and FIRMap diagnostic catheter. The Abbott 3D Mapping System has been designed to enable physicians to view the electrical activity of the heart, thereby supporting the diagnosis and patient-specific treatment planning for a variety of heart arrhythmias including atrial fibrillation, atrial flutter, atrial tachycardia and ventricular tachycardia.

The Abbott 3D Mapping System received FDA Clearance in 2013 band is now in routine use at several leading medical centers throughout the United States.


The CONFIRM Trial1


Study Goal

The study authors hypothesized that human atrial fibrillation (AF or Afib) may be sustained by localized sources known as electrical rotors and focal impulses. Elimination of these sources called focal impulse and rotor modulation (FIRM) may improve patient outcomes.


Catheter ablation is one of various treatments for atrial fibrillation and its success is limited partly because of uncertainty in the mechanisms that sustain AF. The authors developed a computational approach to map the electrical wave fronts during AF. They then prospectively tested whether the targeting patient-specific mechanisms revealed by mapping would improve the results of AF ablation.


Ninety-two subjects were recruited during 107 consecutive ablation procedures for paroxysmal or persistent AF (72%). Cases were prospectively treated, in a 2-arm, 1:2 design, by ablation at sources (FIRM-guided therapy) followed by conventional ablation (n = 36), or conventional ablation alone (n = 71, FIRM-blinded therapy).

Key Findings

  • The CONFIRM Trial demonstrated that AF may be sustained by rotors and focal impulses
  • Conventional Ablation vs. FIRM-guided Ablation
    • 66% Persistent in Conventional arm
    • 81% Persistent in FIRM-guided arm
  • Stable rotors were identified in 97.7% of patients


Localized electrical rotors and focal impulse sources are prevalent sustaining mechanisms for human AF. The findings offer a novel mechanistic framework of treatment for AF.

  1. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel W-J, and Miller JM. Treatment of Atrial Fibrillation by the Ablation of Localized Sources-CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) Trial. J Am Coll Cardiol 2012; 60(7):628-3


The CONFIRM trial was supported by grants to the lead author from the National Institutes of Health and the Doris Duke Charitable Foundation. Please refer to the study citations to review all reported author conflicts of interest.